AbbVie (NASDAQ:ABBV) is in the midst of a transition. AbbVie began life about a decade ago when it was spun off from health care and medical devices company Abbott (NYSE:ABT). Now, however, AbbVie must adapt quickly or ABBV stock will be in big trouble. Up until recently, AbbVie relied on its blockbuster Humira drug for around 60% of its revenue. However, it could lose most of those sales over the next few years, as Humira’s patent protection will disappear in 2023.
AbbVie simply can’t be judged based on its 2019 earnings and dividend. The real question is what its results will look like in 2023 and 2024 as its revenue starts to plunge during the beginning of the post-Humira era. I’ve seen little evidence indicating that it will be able to replace its current profits after the patent cliff arrives. The Allergan deal looks like a risky and potentially even desperate measure. For a company with debt and declining revenues, an easy fix is reducing the dividend.
Source: InvestorPlace
Related Articles:
- Why We Are Dividend Growth Investors
- 3 Higher Yielding, Lower Risk Stocks To Perk Up Your Dividend Income
- Don't Touch These 3 Dividend Stocks!
- 4 Higher Yielders With A Low Free Cash Flow Payout
- 2 Dividend Stocks Headed In The Right Direction
________________________________________________________________
Subscribe to:
Post Comments (Atom)
Popular Posts Last 30 Days
-
How do you assess risk? Different investors have different approaches, and when a Black Swan event topples the market, risk assessment becom...
-
Today, we’ll look at three high-yield dividend stocks that have earned a ‘perfect 10’ from the Smart Score. For investors seeking a clear fo...
-
Many companies have been suspending their dividends during the COVID-19 crisis, and in many cases it is understandable. In times of economic...
-
With the price of oil rebounding, I wanted to find five cheap energy stocks that have solid dividend yields. In other words, the dividends a...
-
While near-term fluctuations in the stock market can be unpredictable, dividends are one of the few reliable sources of market returns. Stoc...
-
AbbVie (NASDAQ:ABBV) is in the midst of a transition. AbbVie began life about a decade ago when it was spun off from health care and medical...
-
“Research shows that dividend cuts are associated with significant share price declines on announcement,” Cornell University Professor of Fi...
-
3M Company (NYSE:MMM) is growing its FCF very well, and as a result, MMM stock is likely to move up at least 44% over the next or so. Right ...
-
With interest rates at historic lows and bond-yields heading down quickly, the payouts from dividend stocks are becoming more and more appea...
-
Dividend investing is a great way for investors to earn reliable income. Dividend stocks tend to have stable, cash-generating business model...
0 comments
Post a Comment
Post a Comment
Note: Only a member of this blog may post a comment.